The partnership with Tokyo Medical University is a strategic move for Xenetic Biosciences, as it could enhance the development of its DNase-based oncology platform. This collaboration may lead to advancements in treating Ewing Sarcoma, potentially increasing investor confidence and positively impacting the stock price in the short term.